Pentasa in Lieu of Sulfasalazine
Authors: Chris J.J. Mulder, Guido N.J. Tytgat, Willem Dekker, Ido J. Terpstra
Journal: Annals of Internal Medicine (1988)

Letters and Corrections1 June 1988Pentasa in Lieu of SulfasalazineCHRIS J.J. MULDER, GUIDO N.J. TYTGAT, WILLEM DEKKER, IDO J. TERPSTRACHRIS J.J. MULDERSearch for more papers by this author, GUIDO N.J. TYTGATSearch for more papers by this author, WILLEM DEKKERSearch for more papers by this author, IDO J. TERPSTRASearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-6-911_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: 5-Aminosalicylic acid (5-ASA) is the effective moiety of sulfasalazine. The sulfapyridine moiety is usually considered to be the cause of intolerance in most of the patients who have side-effects from sulfasalazine therapy (1). Slow-release 5-ASA products have been developed, therefore, to bypass these problems. Pentasa (Gist-Brocades, the Netherlands) consists of 5-ASA microencapsulated in ethyl cellulose. Release of 5-ASA increases as the product travels down the intestine into a median with rising pH (2). We studied whether patients intolerant to sulfasalazine could tolerate Pentasa.Seventy-one patients, aged 18 to 75 years, were entered into the study. The reasons...References1. DASEASTWOODMCMANUSSIRCUS KMJW. Adverse reactions during salicylazosulfapyrine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491-5. CrossrefMedlineGoogle Scholar2. RASMUSSENBONDESENHVIDBERG SSE. 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062-70. CrossrefMedlineGoogle Scholar3. SINGLETONLAWKELLEYMEKHJIANSTURDEVANT JDMHR. National Co-operative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology, 1979;77:870-82. CrossrefMedlineGoogle Scholar4. TURUNENELOMAAANTILLASEPPÄLA UIVK. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol. 1987;22:798-802. CrossrefMedlineGoogle Scholar5. MULDERTYTGATWETERMAN CGI. Double-blind evaluation of slow-release 5-aminosalicylic acid (PentasaR) and salazopyridin (SalazopyrinR) in the treatment of patients suffering from ulcerative colitis. Gastroenterology. 1988. In press. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Academic Medical Center Amsterdam Elizabeth Gasthuis Haarlem the Netherlands PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisProlonged-Release Mesalazine*Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative ColitisGastrointestinal drugsDouble-Blind Comparison of Slow-Release 5-Aminosalicylateand Sulfasalazine in Remission Maintenance in Ulcerative Colitis 1 June 1988Volume 108, Issue 6Page: 911-912 Issue Published: 1 June 1988 PDF DownloadLoading ...